Trials / Recruiting
RecruitingNCT06928675
Cell-free DNA in Acute Stroke
CANTO - Cell-free DNA in Acute Stroke
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
Conditions
Timeline
- Start date
- 2025-03-30
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2025-04-15
- Last updated
- 2025-04-15
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06928675. Inclusion in this directory is not an endorsement.